Predictive Biosciences plans to use its now-completed $25 million Series C round to begin commercializing its biomarker-based bladder cancer test.Predictive Biosciences completed a $25 million Series C round, saying it plans to use the money to complete clinical trials for its CertNDx bladder cancer assay and ready it for market.The assay reduces the need to [...]

Predictive Biosciences Inc., the Lexington, Mass., company that is commercializing biomarker and other non-invasive diagnostics for cancer management, has acquired OncoDiagnostic Laboratory Inc. in Cleveland for undisclosed terms.